PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Acta Anaesthesiol Taiwan. Author manuscript; available in PMC 2014 May 8.
Published in final edited form as:
PMCID: PMC4014005
NIHMSID: NIHMS577742

MU OPIOID RECEPTORS IN PAIN MANAGEMENT

Abstract

Most of the potent analgesics currently in use act through the mu opioid receptor. Although they are classified as mu opioids, clinical experience suggests differences among them. The relative potencies of the agents can vary from patient to patient, as well as the side-effect profiles. These observations, coupled with pharmacological approaches in preclinical models, led to the suggestion of multiple subtypes of mu receptors. The explosion in molecular biology has led to the identification of a single gene encoding mu opioid receptors. It now appears that this gene undergoes extensive splicing, in which a single gene can generate multiple proteins. Evidence now suggests that these splice variants may help explain the clinical variability in responses among patients.

Introduction

Opiates have been used to manage pain for centuries. Opium, which contains a number of alkaloids including morphine and codeine, was eaten, smoked and used as a tincture. Following isolation, morphine and codeine, are used individually. Thousands of analogs have been generated in an effort to avoid some of the difficulties encountered with opiate use, such as respiratory depression, sedation and constipation. Most of these agents act through mu opiate receptors, as defined by the selectivity of their binding for the three classes of opioid receptors that have been cloned. This is to be expected since the structure of morphine is used as a template for the synthesis of most of them. Clinicians have long observed that patients can have markedly varying responses to mu opioids. Some patients may encounter severe side effects such as nausea and vomiting with one agent, while having no difficulties at all with the other. For example, it is not uncommon to find patients with severe nausea/vomiting from morphine tolerating methadone without problems. In addition, the analgesic activity of the opioids also can vary among patients. One patient may find one mu opioid to be quite effective while a different drug may not work anywhere near as well. However, the same drug may not be the best for all patients. This variability among patients has led to accepted paradigm that analgesics need to be individualized. Opioid Rotation also illustrates differences among the mu opioids. In Opioid Rotation patients highly tolerant to one opioid a switch to a different opioid, often restors the analgesic effectiveness and sensitivity.1,2 While all mu drugs display tolerance with prolonged dosing, cross tolerance is incomplete. That is, the tolerance to the second drug may not be as pronounced as the first, explaining why the switch is effective. All these features have raised questions about the mechanisms of these drugs, specifically how a single mu receptor could mediate these actions.

EARLY STUDIES OF MU OPIATE RECEPTOR AND MULTIPLICITY

The first opioid receptor identified in binding assays in 19733-5 were mu receptors. A receptor for the opiates had been predicted years earlier from a variety of traditional pharmacological approaches and the rigid structure activity studies of morphine and related chemical scaffolds.6-8 Since the studies used morphine-related probes, it is not surprising that the receptors were mu. However, several other families of opioid receptors have also been identified (Table 1). In vivo studies led Martin to propose the existence of kappa receptors, in addition to the mu receptors.9,10 Delta receptors, which are selective for the enkephalins, were identified11 after the isolation and identification of endogenous opioids.12-14 Indeed, it turns out that the endogenous ligand for the kappa receptors is another endogenous opioid, dynorphin A.15,16 Work is in progress developing new selective delta and kappa opioids for clinical use, but for the most part the drugs available clinically are mu. There are several mixed agonists/antagonists that interact with both mu and kappa receptors, but they have limited use.

Table 1
Classification of the opioid receptor families

The first suggestion that there may be more than one class of mu receptors coming from receptor binding studies in the mid 1970s that revealed a novel site with unusual characteristics.17 Although mu drugs like morphine labeled it with high potency, confirming its classification as a mu receptor, its ability to bind other drugs clearly distinguished it from the original mu receptor seen in receptor binding assays. The new site was termed mu1 while the original morphine-selective site was termed mu2.18 Understanding the pharmacological significance of these two mu receptors was facilitated by the development of selective antagonists that could selectively block the mu1 site and not the mu2 site.19-21 The naloxonazine-sensitive site corresponds to the mu1 site while the naloxonzine-insensitive mu site is mu2. When given in vivo, these antagonists blocked morphine analgesia, but not respiratory depression or the inhibition of gastrointestinal transit or many of the signs of physical dependence.22-27 Together, these studies implied that drugs such as morphine were acting through more than one mu receptor.

MOLECULAR BIOLOGY OF MU OPIATE RECEPTORS

The opiate receptors were first cloned in 1992 with the isolation of the delta receptor DOR-1 by two independent groups.28,29 This initial report confirmed the existence of the receptors within the G-protein coupled receptor family, one of the largest families of receptors known. Based upon these structures, the other members of the opiate receptor family were quickly cloned, including the mu30-32 and the kappa1 receptors.33-35 Soon after, yet another receptor was identified with a strong homology to the opiate receptors36-41 but which was subsequently found to have a previously unknown peptide as its endogenous ligand, orphanan FQ/nociceptin.42,43

The most important class of opiate receptors that clinically remains is the class of mu receptors. Most of the drugs used clinically act through these receptors and understanding their actions is important in defining their pharmacology. Pharmacological studies suggested more than one class of mu opiate receptor. This has now been confirmed at the molecular level. Although only a single mu receptor gene has been reported, the receptor undergoes extensive alternative splicing to generate a host of splice variants (Fig 1).

Figure 1
Schematic of the human mu opioid receptor (OPRM1) gene structure and alternative splicing

Following the cloning of MOR1 much effort was placed on confirming its pharmacological relevance. The first studies involved using an antisense approach in which very short sequences of antisense targeted specific sequences of the mRNA, leading to its degradation.44,45 These initial reports quickly established that MOR-1 was critical in the production of morphine analgesia. However, the antisense approach can be used more extensively to perform antisense mapping to assess the presence of specific exons within the mRNA responsible for making a protein.46-48 Certain exon targets were important in morphine analgesia, including exons 1 and 4. However, antisense probes targeting exons 2 and 3 had little effect on morphine even though they significantly diminished the activity of heroin and morphine-6β-glucuronide. Thus, at the molecular level there does appear to be receptor differences for these mu opiates.

The association of MOR-1 with morphine analgesia was further confirmed by the generation of several different knock-out animals in which the MOR-1 gene was disrupted. In all of these different knockout animals, which targeted exons 1, 2 and/or 3, morphine lost all activity.49-52 However, in one exon1 knockout mouse, heroin and M6G were still analgesic. This was quite confusing and it was initially suggested that these drugs were activating alternative opioid receptors, such as delta or kappa1. This possibility was eliminated with the finding that the residual heroin and morphine-6β-glucuronide analgesia remained in a triple knockout mouse, which had the same disruption of exon 1 or MOR-1 and additional disruptions of the delta (DOR-1) and kappa1 (KOR-1) receptors. What made this particular knockout mouse interesting was the continuous presence of a number of MOR-1 splice variants.52 Some of these, under the control of the exon 11 pomoter, do not contain exon 1, perhaps explaining their continuous expression.

The splice variants associated with the mu opiate receptor can be separated into two categories based upon their promoter. The gene encoding MOR-1 is quite complex with two distinct promoters. The primary one is associated with exon 153,54 and generates a number of variants that are spliced at the 3’ end in mice, rats and humans (Fig 1).55-62 These are interesting from several perspectives. They are full length seven transmembrane domain G-protein coupled receptors. Structurally, they differ only at the very tip of the intracellular C-terminus. The initial opiate receptor cloned, MOR-1, contains twelve amino acids at the very tip of the C-terminus encoded by exon 4 (Fig 2). In the other C-terminus spliced variants, these twelve amino acids are replaced with different sequences of varying lengths. However, these differences are quite limited and the basic structure of the receptor with its seven transmembrane domains and binding pocket are identical among them (Fig. 2). Thus, these splice variants share a common binding pocket and they all show high affinity and selectivity for mu opiates, as shown in receptor binding assays. Although the splicing has little effect upon the ability of the mu opioids to bind to the receptor, the small structural differences do impact the ability of mu opioids to activate the different splice variants. These differences in the activation profiles of various mu opioids for the receptor variants may help explain the subtle, but clear, differences among the various mu opioids seen clinically.

Fig 2
Schematic of the human OPRM1 carboxyl terminal splice variants’ structures and amino acid sequences predicted from downstream exons of exon 3

The second set of variants are associated with exon 11, which is located approximately 30 kilobases upstream of exon 1.57,63 These variants include a number with quite unique structures. Unlike the exon 1-associated variants, which all encode full length, 7 transmembrane domain receptors, many of the exon 11-associated variants generate truncated variants with only 6 transmembrane domains. Despite their unique structure, there is much evidence now to suggest that they are pharmacologically important. This derives from studies on mice in which all the exon 11-containing variants are lost due to disruption of this region of the gene (Table 2).64 Interestingly, morphine analgesia was not affected. However, the analgesic actions of heroin and the morphine metabolite morphine-6β-glucuronide were significantly reduced. Looking at the drugs, it is apparent that the analgesic actions of mu opioids can be differentiated at the molecular level.

Table 2
Opioid analgesia in MOR-1 knockout mice

THE FUTURE

Pain management remains an art, dependent upon the individualization of care. Not all patients can be managed with the same drugs. Indeed, the complexity of the clinical responses has long been evident. Many factors may play a role, but evidence is accumulating that much of this variability may result from the complexity of mu receptors. Early work from our laboratory proposed two subtypes, mu1 and mu2, based upon selective antagonists.18,20,65 Studies showing differences between morphine and morphine-6β-glucuronide further implied a third subtype.48,66,67 However, the molecular biology of the mu opioid receptor gene reveals the existence of dozens of mu receptor splice variants. Correlating these splice variants to the pharmacologically defined receptors has proven difficult. However, it seems likely that they play an important role in why patients respond so differently. As our understanding progresses, the critical question is whether or not we can utilize this knowledge to develop novel and useful analgesic lacking the detrimental actions of the currently available drugs.

Acknowledgements

This work was supported, in part, from grants from the National Institute on Drug Abuse to GWP (DA02615, DA07242, DA06241 and DA00220) and YXP (DA013997 and DA029244).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Fine PG, Portenoy RK. Establishing “best practices” for opioid rotation: conclusions of an expert panel. J.Pain Symptom.Manage. 2009;38:418–425. [PubMed]
2. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J.Clin.Oncol. 2001;19:2542–2554. [PubMed]
3. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science. 1973;179:1011–1014. [PubMed]
4. Simon EJ, Hiller JM, Edelman I. Stereospecific binding of the potent narcotic analgesic [3H]etorphine to rat-brain homogenate. Proc.Natl.Acad.Sci.USA. 1973;70:1947–1949. [PubMed]
5. Terenius L. Characteristics of the “receptor” for narcotic analgesics in synaptic plasma membrane from rat brain. Acta Pharmacol.et toxicol. 1973;33:377–384. [PubMed]
6. Beckett AH, Casy AF. Synthetic analgesics: sterochemical considerations. J.Pharm.Pharmacol. 1954;6:986–1001. [PubMed]
7. Portoghese PS. A new concept on the mode of interaction of narcotic analgesics with receptors. Unknown. 1965;8:609–616. [PubMed]
8. Goldstein A, Lowney LI, Pal BK. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proc.Natl.Acad.Sci.USA. 1971;68:1742–1747. [PubMed]
9. Martin WR. Opioid Antagonists. Pharmacol.Rev. 1967;19:463–521. [PubMed]
10. Gilbert PE, Martin WR. The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog. J.Pharmacol.Exp.Ther. 1976;198:66–82. [PubMed]
11. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977;267:495–499. [PubMed]
12. Pasternak GW. Opioids and opioid receptors: Neuroscience Research Program. 1974.
13. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975;258:577–579. [PubMed]
14. Terenius L. Effect of peptides and amino acids on dihydromorphine binding to the opiate receptor. J.Pharm.Pharmacol. 1975;27:450–452. [PubMed]
15. Lowney LI, Gentleman SB, Goldstein A. A pituitary endorphin with novel properties. Life Sci. 1979;24:2377–2384. [PubMed]
16. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc.Natl.Acad.Sci.USA. 1979;76:6666–6670. [PubMed]
17. Pasternak GW, Snyder SH. Identification of a novel high affinity opiate receptor binding in rat brain. Nature. 1975;253:563–565. [PubMed]
18. Wolozin BL, Pasternak GW. Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc.Natl.Acad.Sci.USA. 1981;78:6181–6185. [PubMed]
19. Pasternak GW, Childers SR, Snyder SH. Multiple opiate receptors: evidence for mediation of analgesia by a subpopulation of receptors. In: Way EL, editor. Endogenous and Exogenous Opioid Agonists and Antagonists. Pergamon Press; 1979. pp. 113–116.
20. Pasternak GW, Childers SR, Snyder SH. Naloxazone, a long-acting opiate antagonist: Effects on analgesia in intact animals and on opiate receptor binding in vitro. J.Pharmacol.Exp.Ther. 1980;214:455–462. [PubMed]
21. Hahn EF, Carroll-Buatti M, Pasternak GW. Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines. J.Neurosci. 1982;2:572–576. [PubMed]
22. Hahn EF, Pasternak GW. Naloxonazine, a potent, long-acting inhibitor of opiate binding sites. Life Sci. 1982;31:1385–1388. [PubMed]
23. Ling GSF, Spiegel K, Nishimura S, Pasternak GW. Dissociation of morphine's analgesic and respiratory depressant actions. Eur.J.Pharmacol. 1983;86:487–488. [PubMed]
24. Wood PL, Pasternak GW. Specific mu2 opioid isoreceptor regulation of nigrostraital neurons: in vivo evidence with naloxonazine. Neurosci.Lett. 1983;37:291–293. [PubMed]
25. Ling GSF, MacLeod JM, Lee S, Lockhart SH, Pasternak GW. Separation of morphine analgesia from physical dependence. Science. 1984;226:462–464. [PubMed]
26. Ling GSF, Spiegel K, Lockhart SH, Pasternak GW. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J.Pharmacol.Exp.Ther. 1985;232:149–155. [PubMed]
27. Ling GSF, Simantov R, Clark JA, Pasternak GW. Naloxonazine actions in vivo. Eur.J.Pharmacol. 1986;129:33–38. [PubMed]
28. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The δ-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc.Natl.Acad.Sci.USA. 1992;89:12048–12052. [PubMed]
29. Evans CJ, Keith DE, Jr., Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science. 1992;258:1952–1955. [PubMed]
30. Chen Y, Mestek A, Liu J, Hurley JA, Yu L. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol.Pharmacol. 1993;44:8–12. [PubMed]
31. Thompson RC, Mansour A, Akil H, Watson SJ. Cloning and pharmacological characterization of a rat μ opioid receptor. Neuron. 1993;11:903–913. [PubMed]
32. Wang JB, Imai Y, Eppler CM, Gregor P, Spivak CE, Uhl GR. μ opiate receptor: cDNA cloning and expression. Proc.Natl.Acad.Sci.USA. 1993;90:10230–10234. [PubMed]
33. Chen Y, Mestek A, Liu J, Yu L. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the μ and δ opioid receptors. Biochem.J. 1993;295:625–628. [PubMed]
34. Li S, Zhu J, Chen C, Chen Y-W, Deriel JK, Ashby B, Liu-Chen L-Y. Molecular cloning and expression of a rat kappa opioid receptor. Biochem.J. 1993;295:629–633. [PubMed]
35. Meng F, Xie G-X, Thompson RC, Mansour A, Goldstein A, Watson SJ, Akil H. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc.Natl.Acad.Sci.USA. 1993;90:9954–9958. [PubMed]
36. Bunzow JR, Saez C, Mortrud M, Bouvier C, Williams JT, Low M, Grandy DK. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ, δ or kappa opioid receptor type. FEBS Lett. 1994;347:284–288. [PubMed]
37. Chen Y, Fan Y, Liu J, Mestek A, Tian M, Kozak CA, Yu L. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett. 1994;347:279–283. [PubMed]
38. Fukuda K, Kato S, Mori K, Nishi M, Takeshima H, Iwabe N, Miyata T, Houtani T, Siguimoti T. cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett. 1994;343:42–46. [PubMed]
39. Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, Caput D, Vassart G, Meunier JC. ORL-1, a novel member of the opioid family: cloning, functional expression and localization. FEBS Lett. 1994;341:33–38. [PubMed]
40. Pan Y-X, Cheng J, Xu J, Pasternak GW. Cloning, expression and classification of a kappa3-related opioid receptor using antisense oligodeoxynucleotides. Regul.Pept. 1994;54:217–218.
41. Pan Y-X, Cheng J, Xu J, Rossi GC, Jacobson E, Ryan-Moro J, Brooks AI, Dean GE, Standifer KM, Pasternak GW. Cloning and functional characterization through antisense mapping of a kappa3-related opioid receptor. Mol.Pharmacol. 1995;47:1180–1188. [PubMed]
42. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B, Mazargull H, Vassart G, Parmentier M, Costentin J. Isolation and structure of the endogenous agonist of the opioid receptor like ORL1 receptor. Nature. 1995;377:532–535. [PubMed]
43. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ, Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 1995;270:792–794. [PubMed]
44. Rossi GC, Pan Y-X, Cheng J, Pasternak GW. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci. 1994;54:L375–L379. [PubMed]
45. Uhl GR, Childers S, Pasternak GW. An opiate-receptor gene family reunion. Trends Neurosci. 1994;17:89–93. [PubMed]
46. Standifer KM, Chien C-C, Wahlestedt C, Brown GP, Pasternak GW. Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron. 1994;12:805–810. [PubMed]
47. Rossi GC, Standifer KM, Pasternak GW. Differential blockade of morphine and morphine-6β-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein α subunits in rats. Neurosci.Lett. 1995;198:99–102. [PubMed]
48. Rossi GC, Pan Y-X, Brown GP, Pasternak GW. Antisense mapping the MOR-1 opioid receptor: Evidence for alternative splicing and a novel morphine-6β-glucuronide receptor. FEBS Lett. 1995;369:192–196. [PubMed]
49. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dollé P, Tzavara E, Hanoune J, Roques BP, Kieffer BL. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature. 1996;383:819–823. [PubMed]
50. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR. Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc.Natl.Acad.Sci.USA. 1997;94:1544–1549. [PubMed]
51. Loh HH, Liu HC, Cavalli A, Yang WL, Chen YF, Wei LN. μ opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Mol.Brain Res. 1998;54:321–326. [PubMed]
52. Schuller AG, King MA, Zhang J, Bolan E, Pan YX, Morgan DJ, Chang A, Czick ME, Unterwald EM, Pasternak GW, Pintar JE. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat.Neurosci. 1999;2:151–156. [PubMed]
53. Liang Y, Mestek A, Yu L, Carr LG. Cloning and characterization of the promoter region of the mouse μ opioid receptor gene. Brain Res. 1995;679:82–88. [PubMed]
54. Mayer P, Schulzeck S, Kraus J, Zimprich A, Höllt V. Promoter region and alternatively spliced exons of the rat μ-opioid receptor gene. J.Neurochem. 1996;66:2272–2278. [PubMed]
55. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience. 2005;133:209–220. [PubMed]
56. Pan Y-X, Xu J, Rossi GC, Leventhal L, Wan B-L, Zuckerman A, Pasternak GW. Cloning and expression of a novel splice variant of the mouse mu-opioid receptor (MOR-1) gene. Soc.Neurosci. 24:524–1998.
57. Pan Y-X, Xu J, Mahurter L, Bolan EA, Xu MM, Pasternak GW. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc.Natl.Acad.Sci.U.S.A. 2001;98:14084–14089. [PubMed]
58. Pan YX, Xu J, Bolan EA, Abbadie C, Chang A, Zuckerman A, Rossi GC, Pasternak GW. Identification and characterization of three new alternatively spliced mu opioid receptor isoforms. Mol.Pharmacol. 1999;56:396–403. [PubMed]
59. Pan YX, Xu J, Mahurter L, Xu M, Gilbert AK, Pasternak GW. Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem.Biophys.Res.Commun. 2003;301:1057–1061. [PubMed]
60. Pan YX, Xu J, Bolan E, Moskowitz HS, Xu M, Pasternak GW. Identification of four novel exon 5 splice variants of the mouse mu-opioid receptor gene: functional consequences of C-terminal splicing. Mol.Pharmacol. 2005;68:866–875. [PubMed]
61. Pan YX, Xu J, Bolan E, Chang A, Mahurter L, Rossi G, Pasternak GW. Isolation and expression of a novel alternatively spliced mu opioid receptor isoform. MOR-1F, FEBS Lett. 2000;466:337–340. [PubMed]
62. Pasternak DA, Pan L, Xu J, Yu R, Xu MM, Pasternak GW, Pan YX. Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: dissociation of affinity and efficacy. J.Neurochem. 2004;91:881–890. [PubMed]
63. Xu J, Xu M, Hurd YL, Pasternak GW, Pan YX. Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. J.Neurochem. 2009;108:962–972. [PMC free article] [PubMed]
64. Pan YX, Xu J, Xu M, Rossi GC, Matulonis JE, Pasternak GW. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc.Natl.Acad.Sci.U.S.A. 2009;106:4917–4922. [PubMed]
65. Pasternak GW, Childers SR, Snyder SH. Opiate analgesia: Evidence for mediation by a subpopulation of opiate receptors. Science. 1980;208:514–516. [PubMed]
66. Rossi GC, Leventhal L, Pan YX, Cole J, Su W, Bodnar RJ, Pasternak GW. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6beta-glucuronide antinociception. J.Pharmacol.Exp.Ther. 1997;281:109–114. [PubMed]
67. Rossi GC, Brown GP, Leventhal L, Yang K, Pasternak GW. Novel receptor mechanisms for heroin and morphine-6β -glucuronide analgesia. Neurosci.Lett. 1996;216:1–4. [PubMed]
68. Pan Y-X, Pasternak GW. Molecular Biology of Mu Opioid Receptors. In: Pasternak GW, editor. The Opiate Receptors. Humana Press 2nd; 2011.